Skip to content

Geron GERN Additional Paid-In Capital

Additional Paid-In Capital at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$46.37B+0.8%
Incyte logo
IncyteINCY
$5.08B+10.8%
Immunome logo
ImmunomeIMNM
$1.37B+58.5%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$1.59B+4.6%
Celcuity logo
CelcuityCELC
$555.22M+40.4%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$1.04B+46.9%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's additional paid-in capital?
Geron (GERN) reported additional paid-in capital of $2.09B in Q1 2026.
How has Geron's additional paid-in capital changed year-over-year?
Geron's additional paid-in capital increased by 1.4% year-over-year, from $2.06B to $2.09B.
What is the long-term trend for Geron's additional paid-in capital?
Over 5 years (2020 to 2025), Geron's additional paid-in capital has grown at a 8.8% compound annual growth rate (CAGR), from $1.37B to $2.08B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.